简介:针对现行侦察手段对敌方海洋移动目标进行地理坐标的测量方法不多,测量精度不高的问题,提出了一种利用反舰巡航导弹搭载北斗卫星定位接收机(COMPASS)、合成孔径雷达(SAR)、脉冲多普勒雷达(PD)、高重频激光测距仪(HRLR)、激光测高仪(LHD)与数据传输系统(DCS),实现对敌海洋移动目标准确识别和精确定位的方法,介绍了侦察导弹的组成,说明了定位原理,给出了物理多站连续交会定位算法模型,进行了模拟测量数据解算和误差分析。通过仿真证明,本方法简单、实用,能够满足实际工程应用的需求,可为海上远程精确打击体系提供高精度的目标位置信息。
简介:TheCOMPASSexperimentatCERNisstartingdatatakinginsummer2001,TheCOMPASSoff-lineframework(CORAL)willusetheCERNConditionsDataBase(CDB)tohandletimedependentquantitieslikecalibrationconstantsanddatafromtheslowcontrolsystem.WedescribetheuseoftheCDBwithinCORALandthefullscaleperformancetestsontheCOMPASSComputingFarm(CCF),TheCDBhasbeeninterfacedtotheSCADAPVSSslowcontrolsystem.TocontinuouslytransferallthedatatotheCDBandmakethemavailabletotheusers,Wedescribethisinterface,afeasibilitystudyperformedusingmockdataandwepredicttheexpectedperformance.
简介:胃癌是导致癌症患者死亡的主要疾病之一,而现有的治疗手段有限。当前免疫检测点抑制剂在肿瘤的治疗中取得了突破进展,相关研究迅速覆盖到胃癌。针对免疫检查点抗程序性死亡分子1(PD-1)/PD-1配体(PD-L1)抗体的临床研究正在广泛开展。本文对胃癌发生的免疫机制,PD-1/PD-L1表达,抗PD-1/PD-L1抗体早期临床研究及抗PD-1/PD-L1抗体预测疗效的生物标志物的研究进行文献复习。
简介:摘要鼻咽癌(NPC)是我国头颈部鳞状细胞癌最常见的肿瘤。EB病毒感染是NPC的高危因素,与NPC密切相关。虽然鼻咽癌对放化疗敏感,但是局部晚期的鼻咽癌患者,在局控率和总生存上仍不满意。对鼻咽癌组织程序性死亡因子PD-1和程序性死亡因子配体PD-L1的相关临床研究,有望在鼻咽癌治疗带来新希望。
简介:AbstractBackground:The elimination of Plasmodium vivax malaria requires 8-aminoquinolines, which are contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of acute haemolytic anaemia. Several point-of-care devices have been developed to detect G6PD deficiency. The objective of the present study was to evaluate the performance of two of these devices against G6PD genotypes in Mauritania.Methods:Outpatients were screened for G6PD deficiency using CareStart™ rapid diagnostic test (RDT) and CareStart™ G6PD biosensor in Nouakchott, Mauritania, in 2019-2020. African-type and Mediterranean-type G6PD genotypes commonly observed in Africa were determined by polymerase chain reaction-restriction fragment length polymorphism and sequencing. Qualitative variables were compared using Fisher’s exact test.Results:Of 323 patients (74 males and 249 females), 5 males and 2 homozygous females had the African-type A-genotype: A-(202) in 3 males and 2 females and G6PD A-(968) in 2 males. Among heterozygous females, 13 carried G6PD A-(202), 12 G6PD A-(968), and 3 G6PD A-(542) variants. None had the Mediterranean-type G6PD genotype. Eight had a positive G6PD RDT result, including all 7 hemizygous males and homozygous females with A- or A-A- (0.12 to 2.34 IU/g haemoglobin, according to G6PD biosensor), but RDT performed poorly (sensitivity, 11.1% at the cutoff level of < 30%) and yielded many false negative tests. Thirty-seven (50.0%) males and 141 (56.6%) females were anaemic. The adjusted median values of G6PD activity were 5.72 and 5.34 IU/g haemoglobin in non-anaemic males (n = 35) and non-anaemic males and females (n = 130) with normal G6PD genotypes using G6PD biosensor, respectively. Based on the adjusted median of 5.34 IU/g haemoglobin, the performance of G6PD biosensor against genotyping was as follows: at 30% cut-off, the sensitivity and specificity were 85.7% and 91.7%, respectively, and at 80% cut-off, the sensitivity was 100% while the specificity was 64.9%.Conclusions:Although this pilot study supports the utility of biosensor to screen for G6PD deficiency in patients, further investigation in parallel with spectrophotometry is required to promote and validate a more extensive use of this point-of-care device in areas where P. vivax is highly prevalent in Mauritania.